Representation of Luminera Derm Ltd. and its affiliated companies in a share and asset transaction, pursuant to which Luminera sold its dermal filler portfolio and R&D pipeline to AbbVie Inc. (NYSE: ABBV) unit Allergan Aesthetics, for a consideration of hundreds of millions of dollars. Luminera Derm is an R&D company as well as a manufacturer […]
FBC represented Frutarom Industries Ltd. in its acquisition of Enzymotec Ltd. (NASD: ENZY), for approximately $210 million, at an equity value of approximately $290 million. Enzymotec is a leading global supplier of specialty lipid-based products and solutions. Prior to the merger, Frutarom had acquired approximately 19% of Enzymotec’s shares and announced its intention to make […]
FBC represented the SKY and Kedma Capital private equity funds in a transaction for the purchase of 70% of the shares of S.AL Holdings Ltd., in consideration of approximately NIS 136.5M. The consummation of the transaction is subject to the approval of the Israel Antitrust Authority. S.AL Holdings, a leading company in the field of […]
FBC advises Qualcomm in its acquisition of CSR’s imaging unit for approximately $45M